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toxicities were fatigue; nausea; asthenia, vomiting and arthralgia/ 
myalgia.
More than forty percent of the patients received 2nd line therapy and, 
from those, 23% were responsive to the treatment.
Maintenance therapy with gemcitabine in perfusion for 120 minutes 
versus for 30 minutes both combined with carboplatin, showed similar 
response rates and safety proﬁles.
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Background: NSCLC is a common malignancy worldwide-including 
developing countries like India. The standard treatment of advanced 
stage NSCLC is platinum doublet chemotherapy, one of the most ac-
tive being Gemcitabine- platinum combination. Gemcitabine requires 
conversion by deoxycytidine kinase into its active metabolite. This rate 
limiting step can be circumvented by prolonging infusion duration. 
Methods: In the present study we treated 75 elderly patients (age 60 or 
more) having advanced stage NSCLC with low dose prolonged infu-
sion Gemcitabine (350mg/m2 over 4 hours, Day 1 and Day 8) and stan-
dard dose Carboplatin (AUC-5, Day 1 only) repeated every 3 weeks for 
maximum 6 cycles. 
Results: There were 60 (80%) males and 15 females. Of them 43 were 
between the age of 60 and 65 yrs, 18 between the age of 65 and 70 
whereas 14 patients were above the age of 70 yrs. PS was 1 in 54 and 2 
in 24 cases. Stage wise distribution was 40 (53.3 %) with Stage IV and 
35 (46.7 %) with Stage IIIB. Histopathology was adenocarcinoma in 
46, squamous cell in 14 and not speciﬁed in the remaining 15 patients. 
Of these 75, 30 had signiﬁcant co-morbidities. Chemotherapy was 
administered by medical oncologists in 43 patients and others (other 
oncologists/ non oncologists) in the remaining 32 cases. All 6 cycles 
were completed in 46 (61.33 %) of patients - 33 completed all 6 cycles 
without any dose reduction, 13 completed 6 cycles with dose reduc-
tion and 29 could be goven less than 6 cycles of CT. Partial response 
was seen in 19 ( 25.3 %), stable disease in 36 (48 %) and progressive 
disease in 20 (26.7 %). There was no treatment related mortality. The 
median overall survival was 11 months (range 1 - 34 months). There 
were signiﬁcant differences among patients treated by medical oncolo-
gists (group 1) and by others (group 2). The overall RR was 37.2 % 
(16/43) in Group 1 and 9.4 % (3/32) in Group 2. The median survival 
was 13 months in Group 1 and 6 months in Group 2 (p value = 0.004), 
the overall RR was and the medial OS was 6 months. These differences 
were statistically signiﬁcant. 
Conclusions: We conclude that low dose prolonged infusion gem-
citabine and standard carboplatin combination is an effective treatment 
for patients above the age of 60 years with advanced stage NSCLC. 
Dose intensity impacts on RR as well as overall survival and is best 
optimized when chemotherapy is administered by medical oncologists.
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Background: Docetaxel and gemcitabine combination chemotherapy 
has been reported to be active against non-small cell lung cancer 
(NSCLC) and myelosuppression was the most common dose-limit-
ing toxicity. This prospective phase II study was designed to test the 
hypothesis that better tolerance and increased dose intensity might be 
achieved if patients are treated with weekly administration schedule.
Methods: Consenting patients with stage IIIB/IV or recurrent NSCLC 
received ﬁrst-line chemotherapy with docetaxel 35 mg/m2 and gem-
citabine 600 mg/m2 on days 1, 8 and 15. Treatment was repeated every 
4 weeks, for up to 4 cycles.
Results: Of the 35 patients who started treatment, only 6 patients 
(17%) completed planned 4 cycles of therapy. Other than the comple-
tion of all planned treatment cycles, the main reasons for treatment 
discontinuation were toxicity (43%) and progressive disease (40%). 
The most frequently encountered toxic effects were anemia (52% of pa-
tients), nausea and vomiting (60%), fatigue (71%) and anorexia (57%). 
One patient died of bilateral pneumonitis shortly after the adminis-
tration of ﬁrst cycle. Disease control (objective response and stable 
disease) in the ITT population was achieved in 49% of patients and the 
overall response rate was 29% (95% CI, 14 to 44%). With a median 
follow-up duration of 9.2 months, the median progression-free survival 
was 2.8 (95% CI, 0.7 to 4.8) months and the 1-year survival was 53%.
Conclusion: Weekly schedule of docetaxel and gemcitabine has mod-
est activity in advanced NSCLC. This regimen offered no potential 
advantages over standard treatment approaches.
